Gastroesophageal Junction Cancer

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.

In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.

Adding sintilimab to chemotherapy improved survival compared with placebo among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, phase 3 study results published in JAMA showed.

The addition of pembrolizumab to perioperative chemotherapy failed to significantly extend EFS among patients with locally advanced resectable gastric and gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

The addition of zolbetuximab to capecitabine and oxaliplatin significantly extended PFS and OS for patients with claudin-18.2-positive/HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.

First-line treatment with zolbetuximab added to chemotherapy significantly extended OS and PFS among adults with certain forms of claudin-18.2-positive/HER2-negative gastric adenocarcinoma, results of the phase 3 SPOTLIGHT trial showed.

The addition of zolbetuximab to chemotherapy improved PFS among certain patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

The addition of zolbetuximab to chemotherapy improved PFS among certain patients with gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

The FDA granted fast track designation to CMG901 for treatment of certain patients with gastrointestinal cancers.

The FDA granted regenerative medicine advanced therapy designation to CT041, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.